Europe Leukemia Therapeutics Market

Europe Leukemia Therapeutics Market Size (2024 to 2029)

Europe Leukemia Therapeutics market has been estimated at USD 2.12 Billion in 2024 and is projected to reach USD 3.18 Billion by 2029, at a CAGR of 8.4% during the forecast period from 2024 to 2029.  

Leukemia is commonly caused due to the high exposure to radiation, an unhealthy lifestyle, genetic factors, and environmental conditions. Leukemia cases are more common in adults and are observed to progress with aging. It can be identified by the spread of the diseases and by the type of the blood cell that is affected.

The market for Leukemia Therapeutics in Europe is propelling mainly due to factors like increased innovation and R&D in the oncology sectors and a growing number of biotechnology firms.

But due to factors like the high cost of drugs and treatments along with a large number of entry-to-market barriers, the market growth is feared to diminish.

This research report on the Europe Leukemia Therapeutics Market has been segmented and sub-segmented into the following categories.

Europe Leukemia Therapeutics Market By Disease Condition

• Chronic Lymphatic Leukemia           
• Acute Lymphatic Leukemia              
• Chronic Myeloid Leukemia               
• Acute Myeloid Leukemia  

Europe Leukemia Therapeutics Market By Diagnosis

• CT scan     
• Biopsy       
• MRI            

Europe Leukemia Therapeutics Market By Treatments

• Chemotherapy      
• Radiation therapy
• Immunotherapy   
• Surgery     
• Targeted Therapy
• Bone marrow transplant   
• Stem Cell Therapy

Europe Leukemia Therapeutics Market By Drugs

• Gleevec    
• Sapacitabine           
• GA101       
• Vasaroxine              
• Tosedosat      

Europe Leukemia Therapeutics Market By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to the high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in the leukemia therapeutics market. Gleevec was one of the major market growth contributors, in the drugs category.

Europe holds the second-largest share in the global market. A number of factors such as growing awareness of leukemia screening programs and government support are paving the way for companies to penetrate into the European Leukemia Therapeutics market.

Key players operating in the Europe Leukemia Therapeutics market profiled in this report are Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.